Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

FXII inhibition: multipronged benefits

Helen Philippou

Blood (2021) 138 (2): 107–109.

https://doi.org/10.1182/blood.2021011032

Published: 2021

Journal Articles

Transcriptome Profiling of Pediatric Myeloproliferative Neoplasms Demonstrates Dysregulation of Platelet-Relevant Genes and Enrichment of Inflammatory and JAK2 Mediated Complement Pathways

Nicole Kucine, MD, Amanda R. Leonti, MS, Aishwarya Krishnan, Rhonda E. Ries, MA, Ross L. Levine, MD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 4203.

https://doi.org/10.1182/blood-2019-125103

Published: 2019

Journal Articles

Development Of RNAi Therapeutics Targeting The Complement Pathway

Anna Borodovsky, PhD, Kristina Yucius, Andrew Sprague, James Butler, PhD, Shannon Fishman, BS, Tuyen Nguyen, Akshay Vaishnaw, MD, PhD, Martin Maier, PhD, Rajeev Kallanthottathil, PhD, Satya Kuchimanchi, PhD, Muthiah Manoharan, PhD, Rachel Meyers, PhD, Kevin Fitzgerald, PhD

Blood (2013) 122 (21): 2471.

https://doi.org/10.1182/blood.V122.21.2471.2471

Published: 2013

Journal Articles

Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS

Spero R Cataland, M.D., V. Michael Holers, M.D., Shangbin Yang, Ph.D., Haifeng M Wu, M.D.

Blood (2013) 122 (21): 3552.

https://doi.org/10.1182/blood.V122.21.3552.3552

Published: 2013

Journal Articles

The Alternate Complement Pathway in Thrombotic Thrombocytopenic Purpura

John C. Chapin, MD, Katrina Piskorski, Stephen J Eyler, MD, Richard J. H. Smith, MD, Jeffrey Laurence, MD

Blood (2012) 120 (21): 3342.

https://doi.org/10.1182/blood.V120.21.3342.3342

Published: 2012

Journal Articles

Factor H–related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation

Stefan Heinen, Andrea Hartmann, Nadine Lauer, Ulrike Wiehl, Hans-Martin Dahse, Sylvia Schirmer, Katharina Gropp, Tina Enghardt, Reinhard Wallich, Steffi Hälbich, Michael Mihlan, Ursula Schlötzer-Schrehardt, Peter F. Zipfel, Christine Skerka

Blood (2009) 114 (12): 2439–2447.

https://doi.org/10.1182/blood-2009-02-205641

Published: 2009

Includes: Supplemental data

NARROW

FXII inhibition: multipronged benefits

Transcriptome Profiling of Pediatric Myeloproliferative Neoplasms Demonstrates Dysregulation of Platelet-Relevant Genes and Enrichment of Inflammatory and JAK2 Mediated Complement Pathways

Development Of RNAi Therapeutics Targeting The Complement Pathway

Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS

The Alternate Complement Pathway in Thrombotic Thrombocytopenic Purpura

Factor H–related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation

Email alerts

ASH Publications

American Society of Hematology

FXII inhibition: multipronged benefits

Transcriptome Profiling of Pediatric Myeloproliferative Neoplasms Demonstrates Dysregulation of Platelet-Relevant Genes and Enrichment of Inflammatory and JAK2 Mediated Complement Pathways

Development Of RNAi Therapeutics Targeting The Complement Pathway

Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS

The Alternate Complement Pathway in Thrombotic Thrombocytopenic Purpura

Factor H–related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only